Rigel Pharmaceuticals Inc Market Cap ($882.44 Million)

$882.44 Million USD  · Rank #9155

Market Cap & Net Worth: Rigel Pharmaceuticals Inc (RIGL)

Rigel Pharmaceuticals Inc market cap. Rigel Pharmaceuticals Inc (NASDAQ:RIGL) has a market capitalization of $882.44 Million ($882.44 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9155 globally and #2586 in its home market, demonstrating a 1.46% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rigel Pharmaceuticals Inc's stock price $51.29 by its total outstanding shares 18679864 (18.68 Million). Also see Rigel Pharmaceuticals Inc (RIGL) cash conversion ratio for how efficiently the company converts equity into cash flow.

Rigel Pharmaceuticals Inc Market Cap History (2015–2026)

Rigel Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows growth from $566.00 Million to $958.09 Million (5.00% CAGR). Check Rigel Pharmaceuticals Inc (RIGL) stock price for real-time trading data and today's change.

Index Memberships

Rigel Pharmaceuticals Inc is a constituent of 3 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NASDAQ Health Care
IXHC
$2.62 Trillion 0.03% #259 of 976
NASDAQ Composite
IXIC
$40.12 Trillion 0.00% #972 of 3165
NASDAQ Biotechnology
NBI
$1.84 Trillion 0.05% #150 of 263

Weight: Rigel Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Rigel Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Rigel Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RIGL net assets growth trend to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

2.72x

Rigel Pharmaceuticals Inc's market cap is 2.72 times its annual revenue

Industry average: 4569.38x Lower than industry average

Latest Price to Earnings (P/E) Ratio

2.18x

Rigel Pharmaceuticals Inc's market cap is 2.18 times its annual earnings

Industry average: 1.44x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $444.58 Million $20.38 Million -$69.22 Million 21.81x N/A
2017 $724.78 Million $4.48 Million -$77.99 Million 161.64x N/A
2018 $429.64 Million $44.51 Million -$70.48 Million 9.65x N/A
2019 $399.75 Million $59.29 Million -$66.55 Million 6.74x N/A
2020 $653.80 Million $108.62 Million -$29.74 Million 6.02x N/A
2021 $495.02 Million $149.24 Million -$17.91 Million 3.32x N/A
2022 $280.20 Million $120.24 Million -$58.57 Million 2.33x N/A
2023 $270.86 Million $116.88 Million -$25.09 Million 2.32x N/A
2024 $314.20 Million $179.28 Million $17.48 Million 1.75x 17.97x
2025 $800.06 Million $294.28 Million $367.02 Million 2.72x 2.18x

Competitor Companies of RIGL by Market Capitalization

Companies near Rigel Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see RIGL total assets for a full breakdown of the balance sheet.

Key companies related to Rigel Pharmaceuticals Inc by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
  • CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
  • Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#181 Vertex Pharmaceuticals Inc NASDAQ:VRTX $130.90 Billion $549.04
#373 Regeneron Pharmaceuticals Inc NASDAQ:REGN $76.14 Billion $930.67
#415 CSL Ltd AU:CSL $67.74 Billion AU$197.34
#503 Moderna Inc NASDAQ:MRNA $54.14 Billion $258.38

Market Capitalization of Rigel Pharmaceuticals Inc (2015–2026)

Market capitalization of Rigel Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Rigel Pharmaceuticals Inc's market cap moved from $566.00 Million to $ 958.09 Million, with a yearly change of 5.00%.

Year Market Cap Change (%)
2026 $958.09 Million +19.75%
2025 $800.06 Million +154.64%
2024 $314.20 Million +16.00%
2023 $270.86 Million -3.33%
2022 $280.20 Million -43.40%
2021 $495.02 Million -24.29%
2020 $653.80 Million +63.55%
2019 $399.75 Million -6.96%
2018 $429.64 Million -40.72%
2017 $724.78 Million +63.03%
2016 $444.58 Million -21.45%
2015 $566.00 Million --

End of Day Market Cap According to Different Sources

On Nov 5th, 2026 the market cap of Rigel Pharmaceuticals Inc was reported to be:

Source Market Cap
Yahoo Finance $882.44 Million USD
MoneyControl $882.44 Million USD
MarketWatch $882.44 Million USD
marketcap.company $882.44 Million USD
Reuters $882.44 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Rigel Pharmaceuticals Inc

NASDAQ:RIGL USA Biotechnology
Market Cap
$958.09 Million
Market Cap Rank
#9155 Global
#2586 in USA
Share Price
$51.29
Change (1 day)
+4.97%
52-Week Range
$25.44 - $51.45
All Time High
$51.45
About

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more